Please assess the completion status of the following clinical trial:

Trial Title: Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male subjects or female subjects of non-childbearing potential~* ≥18 and \<55 years of age at the time of consent~* BMI \>18.5 and \<30 kg/m2 and a weight of ≥50 kg for males or ≥45 kg for females~* Sexually active males must use a double barrier method of contraception during the study and for at least 90 days after the last dose of study drug~* Male subjects must be willing not to donate sperm until 90 days following the last study drug administration~Exclusion Criteria:~* Personal or family History of significant medical illness~* Clinically significant abnormalities on screening tests/exams~* History of or significant risk of committing suicide~* Donation of plasma within 7 days prior to dosing~* Donation or significant loss of blood within 30 days prior to the first dosing~* Major surgery within 3 months or minor surgery within 1 month prior to admission~* Use of prohibited prescription, over-the-counter medications or natural health products~* Alcohol-based products 24 hours prior to admission~* Female subjects who are currently pregnant or lactating~* Positive pregnancy test~* Use of tobacco or nicotine products within 3 months prior to Screening~* Significant alcohol consumption~* History of drug abuse within the previous 2 years, or a positive drug screen~* History of allergy to study medications~* Undergoing abrupt discontinuation of alcohol or sedatives~* Not suitable for study in the opinion of the Principal Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: OTHER): ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days~Cohort 1 Probe Cocktail given on 2 separate days:~* midazolam: 1 µg infused IV~* caffeine: 200 mg oral tablet~* omeprazole: two 20 mg oral tablets~* dextromethorphan: 1.6mL (containing \~10 mg) oral solution
- Cohort 2 (Type: OTHER): ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days~Cohort 2 Probe Cocktail given on 3 separate days:~* midazolam: 10 µg/mL given as 1mL oral solution.~* dabigatran: 375 µg/mL and pitavastatin: 10 µg/mL given as 1mL oral solution~* rosuvastatin: 25 µg/mL and atorvastatin: 50 µg/mL given as 2mL oral solution
- Cohort 3 (Type: OTHER): ecopipam HCl oral tablets of 12.5, 50, 75, and 100 mg daily for up to 20 days~Cohort 3 Probe Cocktail given on 2 separate days:~- bupropion: 100mg oral tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).